Search Results

Press Releases

Abpro Announces Closing of Business Combination with Atlantic Coastal Acquisition Corp. II

November 14, 2024

·

2 min read

Genetown

Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination.

January 22, 2024

·

7 min read

Genetown

Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II

Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced a term sheet to enter into a definitive business combination, which was entered into on September 18, 2023.

September 21, 2023

·

6 min read

Drug Development

Celltrion/Abpro, Merck/Nerviano and more Unite against Cancer

Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.

September 21, 2022

·

2 min read

·

Paul Elias

Business

Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody

Abpro announced a strategic partnership with Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea, today, for its cancer molecule ABP 102, an antibody therapy for patients suffering from HER2+ cancer, including breast, gastric, and pancreatic cancer.

September 21, 2022

·

3 min read

Genetown

Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant

Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of its neutralizing antibody candidate, ABP 310’s ability to neutralize the emerging SARS-CoV-2 Omicron variant.

December 9, 2021

·

3 min read

Business

Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders

Abpro Corporation today announced the expansion of its scientific advisory board with additions of infectious disease drug development leaders

November 25, 2020

·

4 min read

Genetown

Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration

Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, announced results from its study of ABP201, a novel bispecific antibody co-targeting VEGF and ANG2, for treatment of wet age-related macular degeneration and diabetic macular edema.

May 4, 2021

·

2 min read

Drug Development

Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19

Abpro Corporation today announced the results of a Phase 1 study demonstrating a favorable safety and pharmacokinetic profile of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV-2 infection.

February 2, 2021

·

3 min read

Genetown

Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets

Abpro to receive up to $1.1 billion, including a $30 million upfront equity investment, clinical funding, milestones, and royalties

March 3, 2020

·

5 min read